2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.27 Agrawal

PP01.27 Agrawal - Abstract

Pdf Summary

Researchers at Memorial Sloan Kettering Cancer Center have investigated the potential of targeting TROP-2 in Diffuse Pleural Mesothelioma (DPM), an aggressive cancer with limited treatment options. They identified TROP-2 as a possible therapeutic target by studying patient-derived xenograft models. TROP-2, a protein associated with tumor progression, was found to be expressed in DPM samples and linked to oncogenic pathways like metastasis and stemness. In preclinical models, an antibody-drug conjugate (ADC) targeting TROP-2, Sacituzumab Govitecan (SG), showed promising results in slowing tumor growth compared to standard chemotherapy. These findings suggest that TROP-2 is a potential target for therapy in DPM. As a result, a phase 2 clinical trial funded by Gilead is planned to evaluate the efficacy of SG in patients with recurrent/metastatic DPM, with the trial expected to begin in early 2024. This research provides the first evidence supporting the potential of TROP-2 as a therapeutic target in mesothelioma, highlighting the need for further clinical exploration.

Keywords

Memorial Sloan Kettering Cancer Center

TROP-2

Diffuse Pleural Mesothelioma

patient-derived xenograft models

oncogenic pathways

Sacituzumab Govitecan

antibody-drug conjugate

metastasis

stemness

phase 2 clinical trial